Respironics® Launches ComfortLite™ 2 Nasal Mask

Multiple Cushion Options and Minimal Facial Contact for Increased Patient Comfort

Murrysville, PA - March 06, 2006

Respironics, Inc. announces the release of the ComfortLite™ 2 minimal-contact nasal mask that helps improve patient outcomes through new and improved features and enhancements. With its multiple cushion options and minimal contact with the patient's face, the new ComfortLite 2 is proof of Respironics' commitment to providing solutions and upgrades to better the lives of patients with Obstructive Sleep Apnea (OSA).

"By offering patients multiple cushion options, reducing facial pressure points and adding a host of more durable and comfortable improvements, the new ComfortLite 2 aims to help patients comply with therapy, which, in turn, may also lead to more successful clinical outcomes," says Laurie Scott, U.S. Marketing Manager, Patient Interface, Respironics.

With the ComfortLite 2, patients are able to choose from several cushion options. The new Pillows Cushion offers patients a flexible pillow design that inserts slightly into the nostrils for an instant and robust seal and easy patient set-up. Sizes for the Pillows Cushion include petite, small, medium and large. Patients choosing the more traditional Simple Cushion™ will find that it rests at the tip of the nose, thus reducing pressure points at the bridge of the nose and the upper lip. The Simple Cushion is available in sizes petite, small, medium and large. And for patients who prefer a "pillows-like" cushion without any insertion into the nostrils, the Direct Seal™ cushion offers a comfortable seal and fit while resting just outside the nostrils. The Direct Seal comes in sizes one through six.

In addition to the multiple cushion options, the ComfortLite 2 distinguishes itself with a unique headgear design that eliminates facial pressure points. By keeping the straps off of the patient's face, the headgear provides a secure comfortable fit without causing unnecessary facial discomfort. And, the ComfortLite 2 relies on the headgear for stability instead of the nostrils, providing a reliable seal without nostril irritation. This not only increases comfort for patients, but also increases their chances for compliance.

The materials and replacement parts of the ComfortLite 2 have all been upgraded over the original ComfortLite to ensure durability and quality. Improvements include the new "Halo" headgear, which provides a comfortable and stable fit that can be configured three ways. Also, the headgear side straps are now made of soft, flexible fabric for maximum comfort - especially for side-sleepers. In addition, the crown swivel has been moved forward to reduce contact with the patient's bed pillow and is made up of new easy-rotating material.

Respironics' Sleep and Home Respiratory Group is recognized worldwide for its continuous stream of medical innovations and advancements in the management of sleep disorders, chronic respiratory problems, and neonatal and pediatric care. The Group integrates state-of-the-art technology in diagnostics, therapy and monitoring with strategic problems to help health care providers, sleep centers and pediatric units care for patients efficiently and cost-effectively.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in more than 130 countries and employs more than 4,200 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.

This document contains forward-looking statements, including statements relating to, among other things, developments in the health care industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); the effects of a major earthquake, cyber-attack or other catastrophic event that results in the destruction or disruption of any of our critical business or information technology systems; foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company's stock price; and third-party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.